Talk Presenting Companies (Theatre A) track
Oncology: FoRx Therapeutics AG
Mon, Nov 9, 2026 · 1:45–2:00 PM CET Koelnmesse
About this session
FoRx Therapeutics is a clinical-stage company that develops next-generation small molecule therapeutics targeting DNA Replication Stress pathways for anti-cancer therapy. The company is based in Basel, Switzerland, and structured as a lean organization with 10 employees and an integrated network of external partners. FoRx's pipeline comprises differentiated, best-in-class as well as novel, first-in-class programs for oncology indications. The company's lead program is a highly potent and selective PARG inhibitor, FORX-428.
